HHS Says FDA Working With Baxter To Identify Potential Products In System, Alternative Manufacturing Sites, Including For Potential Temporary Imports; FDA Will Continue To Work With Baxter As They Bring Their Plant Back Online And With Other Suppliers To Increase Supply
Portfolio Pulse from Benzinga Newsdesk
The FDA is collaborating with Baxter to identify potential products in their system and alternative manufacturing sites, including temporary imports, to address supply issues. The FDA will continue to support Baxter in bringing their plant back online and work with other suppliers to increase supply.
October 09, 2024 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baxter is working with the FDA to identify alternative manufacturing sites and potential temporary imports to address supply issues. The FDA's support in bringing Baxter's plant back online is crucial.
Baxter's collaboration with the FDA to address supply issues and the efforts to bring their plant back online are positive developments. This proactive approach may lead to a resolution of supply constraints, potentially boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90